PCSK9 and familial hypercholesterolemia: The monoclonal antibodies evolocumab and alirocumab are prominent examples of PCSK9 inhibitors, demonstrating robust efficacy in reducing cardiovascular events in patients with hypercholesterolemia and those intolerant to statins [27].